06399061 is referenced by 86 patents and cites 7 patents.

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Preferred anti-CD20 antibodies are the monoclonal anti-body secreted by ATCC Deposit No. HB11388 and the chimeric anti-CD20 antibody secreted by transfectoma TCAE8 accorded ATCC Deposit No. 69119.

Title
Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma
Application Number
8/475815
Publication Number
6399061 (B1)
Application Date
June 7, 1995
Publication Date
June 4, 2002
Inventor
William H Rastetter
Rancho Santa Fe
CA, US
Mitchell E Reff
San Diego
CA, US
Roland A Newman
San Diego
CA, US
Nabil Hanna
Rancho Santa Fe
CA, US
Darrell R Anderson
Escondido
CA, US
Agent
Robin L Teskin
US
Assignee
IDEC Pharmaceutical Corporation
CA, US
IPC
A61K 39/395
View Original Source